Juan Glinka

Juan Glinka

Auto-generated profile, based on publicly available information

Juan Glinka

Department of Surgery, London, Ontario, Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Annals of Hepato-Biliary-Pancreatic Surgery
Verified
Journal Article
Open access
PDF file
JGJuan Glinka
Juan Glinka
RCRodrigo Sanchez Claria
Rodrigo Sanchez Claria
VAVictoria Ardiles
Victoria Ardiles
ESEduardo De Santibañes
Eduardo De Santibañes
JPJuan Pekolj
Juan Pekolj
OMOscar Mazza
Oscar Mazza
Metastasis in the pancreatic gland is infrequent, representing between 2-5% of the tumors that affect this organ. However, secondary lesions of clear cell renal carcinoma (CCRC) can occur mainly in this location and it is frequently the only site of dissemination. Treatment of choice is resection in surgically fit patients, as it has been shown that it improves the quality of life and prognosis substantially. We retrospectively reviewed the clinical data of patients with pancreatic resections for metastatic CCRC since there are no reports of the treatment modality of this singular entity in Argentina. Retrospective cohort analysis over a 10-year period including eight patients who underwent pancreatic resection for metastatic CCRC. 75% of patients were male with an average age of 65.5 years. The pancreatic surgery occurred at a median time of 9.2 years (1-24.8) from the renal operation. The pancreatic lesions were mostly solitary and asymptomatic. A pancreaticoduodenectomy (PD) was performed in 4 patients (50%). Distal pancreatectomy (DP) was performed in 3 patients (37.3%) and one patient (12.5%) underwent a total pancreaticoduodenectomy. All the patients presented a confirmatory biopsy of pancreatic metastasis of CCRC. Complications were recorded in 3 patients (42.85%). No intraoperative or postoperative mortality was registered. With a median follow-up of 45 months, three patients presented recurrence at 32, 46 and 51 months, respectively. Only one patient showed death due to recurrence at 7.8 month. CCRC pancreatic metastases treated surgically have a low morbidity and mortality rate in high volume centers, showing excellent long-term survival.

13 March 2023 in Liver Transplantation
Verified
Journal Article
Closed access
JGJuan Glinka
Juan Glinka
YSYashasavi Sachar
Yashasavi Sachar
ETEphraim Tang
Ephraim Tang
MBMayur Brahmania
Mayur Brahmania
JHJaehyun Hwang
Jaehyun Hwang
ASAnton Skaro
Anton Skaro
Medical assistance in dying (MAiD) has been a legally approved practice in Canada since 2016. Only recently have patients undergoing MAiD also been considered as donors for liver transplantation (LT). This study aimed to evaluate a case series of LT outcomes for recipients with MAiD donors and was paired with a systematic literature review of studies assessing the efficacy of MAiD-associated liver donation. A retrospective chart review of patients registered within the LT Registry at London Health Sciences Centre (LHSC) in London, Ontario, Canada, that had received MAiD donor LT was conducted to develop a case series. Descriptive statistics were produced based on available patient outcomes information. The systematic review included euthanasia due to MAiD being a term exclusive to Canada. Case series had a 100% 1-year graft survival rate, with 50% of patients experiencing early allograft dysfunction but having no significant clinical outcome. A single case of postoperative biliary complication was reported. Median warm ischemic time ranged from 7.8–13 minutes among case series and literature reviews. Utilization of donation after circulatory death allografts procured after MAiD appears to be promising. Mechanisms associated with potential impact in postoperative outcomes include relatively lower warm ischemic time relative to donation after circulatory death Maastricht III graft recipients.

1 February 2024 in Annals of Hepato-Biliary-Pancreatic Surgery
Verified
Journal Article
Open access
EWEvelyn Waugh
Evelyn Waugh
JGJuan Glinka
Juan Glinka
DBDaniel Breadner
Daniel Breadner
RLRachel Liu
Rachel Liu
ETEphraim Tang
Ephraim Tang
ASAnton Skaro
Anton Skaro
While patients with borderline resectable pancreatic cancer (BRPC) are a target population for neoadjuvant chemotherapy (NAC), formal guidelines for neoadjuvant therapy are lacking. We assessed the perioperative and oncological outcomes in patients with BRPC undergoing NAC with FOLFIRINOX for patients undergoing upfront surgery (US). The AHPBA criteria for borderline resectability and/or a CA19-9 level > 100 μ/mL defined borderline resectable tumors retrieved from a prospectively populated institutional registry from 2007 to 2020. The primary outcome was overall survival (OS) at 1 and 3 years. A Cox Proportional Hazard model based on intention to treat was used. A receiver-operator characteristics (ROC) curve was constructed to assess the discriminatory capability of the use of CA19-9 > 100 μ/mL to predict resectability and mortality. Forty BRPC patients underwent NAC, while 46 underwent US. The median OS with NAC was 19.8 months (interquartile range [IQR], 10.3-44.24) vs. 10.6 months (IQR, 6.37-17.6) with US. At 1 year, 70% of the NAC group and 41.3% of the US group survived (p = 0.008). At 3 years, 42.5 % of the NAC group and 10.9% of the US group survived (p = 0.001). NAC significantly reduced the hazard of death (adjusted hazard ratio, 0.20; 95% confidence interval, 0.07-0.54; p = 0.001). CA19-9 > 100 μ/mL showed poor discrimination in predicting mortality, but was a moderate predictor of resectability. We found a survival benefit of NAC with FOLFIRINOX for BRPC. Greater pre-treatment of CA19-9 and multivessel involvement on initial imaging were associated with progression of the disease following NAC.

24 April 2020 in Langenbeck's Archives of Surgery
Verified
Journal Article
Closed access
PDF file
JGJuan Glinka
Juan Glinka
VAVictoria Ardiles
Victoria Ardiles
JPJuan Pekolj
Juan Pekolj
JMJuan Mattera
Juan Mattera
RCRodrigo Sanchez Clariá
Rodrigo Sanchez Clariá
MSMartin de Santibanes
Martin de Santibanes

1 December 2020 in HepatoBiliary Surgery and Nutrition
Verified
Journal Article
Open access
PDF file
JGJuan Glinka
Juan Glinka
VAVictoria Ardiles
Victoria Ardiles
JPJuan Pekolj
Juan Pekolj
ESEduardo de Santibañes
Eduardo de Santibañes
MSMartin de Santibañes
Martin de Santibañes
Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) approach emerged as a promising surgical strategy for rapid and large hypertrophy of the future liver remnant (FLR) when a major liver resection is necessary. Colorectal liver metastasis (CRLM) is their main indication. However, the promising results published so far, are very difficult to interpret since they usually focus on the technique and not on the underlying disease. Moreover, they are usually made up of complex populations, which received different chemotherapy schemes, with the ALPPS technical variations implemented over time and without consistent long-term follow-up results as well. Whereby, its role in CRLM should be analyzed as carefully as possible to indicate and select the best candidates who will benefit the most from this approach. We conducted a computerized search using PubMed and Google Scholar for reports published so far, using mesh headings and keywords related to the ALPPS and CRLM.

7 July 2025 in Annals of Hepato-Biliary-Pancreatic Surgery
Verified
Journal Article
Open access
PDF file
GNGautham Nair
Gautham Nair
AHAli Hadi
Ali Hadi
KGKartik Gupta
Kartik Gupta
ETEdward Tran
Edward Tran
GSGeerthan Srikantharajah
Geerthan Srikantharajah
JGJuan Glinka
Juan Glinka
Gautham Nair, Ali Hadi, Kartik Gupta, Edward Tran, Geerthan Srikantharajah, Evelyn Waugh, Ephraim Tang, Anton Skaro, Juan Glinka. Ann Hepatobiliary Pancreat Surg -0001;0:. https://doi.org/10.14701/ahbps.25-046